Rationale for the use of bisphosphonates in breast cancer

Acta Oncologica

Volumn 35, Issue SUPPL. 5, 1996, Pages 61-67

  Kanis, John A ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; PAMIDRONIC ACID;

ADULT; AGED; BONE METASTASIS; BONE PAIN; BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; FEMALE; HUMAN; HYPERCALCEMIA; PRIORITY JOURNAL; QUALITY OF LIFE;

BONE NEOPLASMS; BONE REMODELING; BREAST NEOPLASMS; CLODRONIC ACID; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; FRACTURES, SPONTANEOUS; HUMANS; HYPERCALCEMIA; OSTEOCLASTS; PAIN; QUALITY OF LIFE;

EID: 0030512278     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869609083972     Document Type: Article

References (32)

1. Kanis JA, O'Rourke N, McCloskey EV. Consequences of neoplasia-induced bone resorption and the use of clodronate. Int J Oncology 5; 713-731, 1994.
2. Paterson AHG: Bone metastases in breast cancer, prostate cancer and myeloma. Bone 8 (suppl 1): 17-22, 1987.
3. Taube T, Elomaa I, Blomqvist C, Beneton MNC, Kanis JA. Comparative effects of clodronate and calcitonin in metastatic breast cancer. Europ J Clin Oncol 29: 1677-1681, 1993.
4. Kanis JA: The Pathophysiology and Treatment of Paget's Disease of Bone. London, Martin Dunitz, 1991.
5. Jacobs TP, Siris ES, Bilezikian JP, Baguiran DC, Shane E, Canfield RE: Hypercalcemia of malignancy: Treatment with intravenous dichloromethylene diphosphonate. Ann Intern Med 94: 312-316, 1981.
6. Stashenko P, Dewhurst FE, Rooney ML, Desjardins LA, Hartley JD. Interleukin-1β is a potent inhibitor of bone formation in vitro. J Bone Mineral Res 2; 559-567, 1987.
7. Taube T, Elomaa I, Blomqvist C, Beneton MNC, Kanis JA. Histomorphometric evidence for osteoclast mediated bone resorption in metastatic breast cancer. Bone 2; 161-166, 1994.
8. Kanis JA. Bone and cancer: pathophysiology and treatment of metastases. Bone 17; 101-105s, 1995.
9. Bonizar Z, Spyratos F, Daytieux S, de Vernejoul M-C, Julienne A. Polymerase chain reaction analysis of parathyroid hormone-related protein gene expression in breast cancer patients and occurrence of bone metastases. Cancer Research 53; 5076-5078, 1993.
10. Nakai M, Mundy GR, Williams PJ, Boyce B, Yoneda T. A synthetic antagonist to laminin inhibits the formation of osteolytic metastases by human melanoma cells in nude mice. Cancer Research 52: 5395-5399, 1992.
11. Mbalaviele G, Sasaki A, Mundy GR, Yoneda T. E cadherim expression by breast cancer cells influences development of bone metastases. Journal of Bone and Mineral Research 9 (suppl 1): S146, 1994.
12. Mundy GR. Calcium homeostasis: hypercalcaemia and hypocalcaemia. 2nd Ed. Martin Dunitz, London.
13. Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyce IT. Cancer associated hypercalcaemia: morbidity and mortality: experience in 126 patients. Ann Intern Med 112; 499-504, 1990.
14. Kanis JA, Cundy T, Heynen G, Russell RGG: The pathophysiology of hypercalcaemia. Metab Bone Dis Rel Res 2: 143-159, 1980.
15. Paterson AHG, Powles TJ, Kanis JA, McCloskey EV, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 11: 59-65, 1993.
16. Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 42: 919-944, 1991.
17. O'Rourke NP. McCloskey EV, Vasikaran S. Eyres K, Fern D. et al. Effective treatment of malignant hypercalcemia with a single intravenous infusion of clodronate. British Journal of Cancer 67: 560-563, 1993.
18. Kanis JA (ed): Clodronate. A new perspective in the treatment of neoplastic bone disease. Bone 8(suppl): 1-86, 1987.
19. Yates AJP, Murray RML, Jorums GJ, Martin TJ. A comparison of single and multiple intravenous infusions of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) in the treatment of hypercalcaemia of malignancy. Australian and New Zealand Journal of Medicine 17: 387-391, 1987.
20. Ralston SH, Gallacher SJ, Patel U, Dryburgh FJ, Frazer WD et al. Comparison of three intravenous bisphosphonates in cancer associated hypercalcaemia. Lancet 2; 1180-1182, 1989.
21. Daragon A, Peyron R, Serrurier D, Deshayes P. Treatment of hypercalcemia of malignancy with intravenous aminohydroxypropylidene bisphosphonate. Results of a stratified, double-blind, randomized two-month dose-response study. Current Therapeutic Research 50: 10-21, 1991.
22. Ernst DS, MacDonald RN, Paterson AHG, Jensen J, Bruera E. A double-blind cross-over trial of IV clodronate in metastatic bone pain. J Pain Sympt Man. 7: 4-11, 1992.
23. Thurlimann B, Morant R, Jungi WF, Radziwill A. Pamidronate for pain control in patients with osteolytic bone disease: a prospective dose-effect study. Support Care Cancer 2: 61-65, 1994.
24. Franceschini R, Corsini G, Cataldi A, Garibaldi A, Cianciosi P, et al. Lack of variation of plasma beta-endorphin after clodronate infusion in patients with increased bone resorption Current Therapeutic Research 54: 214-220, 1993.
25. Clarke NW, Holbrook IB, McClure J, George NJR. Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study. British Journal of Cancer 63: 420-423, 1991.
26. Belch AR, Bergsagel DE, Wilson K, O'Reilly S, Wilson J, Sutton D, Pater J, Johnston D, Zee B. Effect of daily etidronate on the osteolysis of multiple myeloma. J Clin Oncol 9: 1397-1402, 1991.
27. Van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, Cleton FJ, Beex LVAM, Blijham G, Hermans J, Neijt JP, Papapoulos SE, Sleeboom HP. Palliative pamidronate treatment in patients with bone metastases from breast cancer. Journal of Clinical Oncology II: 491-498, 1993.
28. Elomaa I, Blomqvist C, Grohn P, Porkka L, Kairento AL, Selander K, Lamberg-Allardt C, Holmstrom T: Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases. Lancet i: 146-149, 1983.
29. Botturi M, Zanni D, Togi G. Disodium clodronate and radiotherapy in bone metastases from solid tumours. La Radiologia Medica 80; 726-733, 1990.
30. Elomaa I, Blomqvist C, Porkka L, Lamberg-Allardt C, Borgstrom GH: Treatment of skeletal disease in breast cancer: A controlled clodronate trial. Bone 8(suppl): 53-56, 1987.
31. Conte PF, Giannessi PG, Latreille J, Mauriac L, Koliren L, Calabresi F, Ford JM. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial. Annals of Oncology 5 (suppl 7): S41-44, 1994.
32. Biermann WA, Cantor RI, Fellin FM, Jakobowski J, Hopkins L, Newbold RC: An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast. Bone 12 (suppl 1): 37-42, 1991.